Evidence map›Paper›PMID 36342141›Full record

ArticlemSphere2022

Effects of Fluticasone Propionate on

Lesa A Begley, Kristopher Opron, Guowu Bian, Ariangela J Kozik, Cai Liu, Jeremy Felton, Bo Wen, Duxin Sun, Yvonne J Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Microbiome modifications by steroids during viral exacerbation of asthma and in healthy mice.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  5. Observational
  6. Asthma Pathogenesis: Phenotypes, Therapies, and Gaps: Summary of the Aspen Lung Conference 2023.American journal of respiratory cell and molecular biology · 2024
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lesa A BegleyDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Kristopher OpronDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Guowu BianDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Ariangela J KozikDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Cai LiuPharmacokinetics and Mass Spectrometry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Jeremy FeltonPharmacokinetics and Mass Spectrometry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Bo WenPharmacokinetics and Mass Spectrometry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Duxin SunPharmacokinetics and Mass Spectrometry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
Yvonne J HuangDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-7497-6597
University of Michigan · US

Funding

Sputum Microbial Markers of Type 2-Low AsthmaR01AI129958 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUANG, YVONNE JEAN · 2017 to 2021
$3.6M
NIAID NIH HHS R01 AI129958
6 · The paper itself

Abstract

Inhaled corticosteroids (ICS) are commonly prescribed first-line treatments for asthma and chronic obstructive pulmonary disease (COPD). Recent evidence has shown that ICS use is associated with changes in the airway microbiome, which may impact clinical outcomes such as potential increased risk for pneumonia in COPD. Although the immunomodulatory effects of corticosteroids are well appreciated, whether ICS could directly influence the behavior of respiratory tract bacteria has been unknown. In this pilot study we explored the effects of fluticasone proprionate, a commonly prescribed inhaled corticosteroid, on respiratory bacteria with an expanded focus on Klebsiella pneumoniae, a species previously implicated in fluticasone-associated pneumonia in COPD. We observed significant effects of fluticasone proprionate on growth responses of

Indexed as

AsthmaPneumoniaPulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesFluticasoneHumansKlebsiella pneumoniaePilot ProjectsAdrenal Cortex HormonesFluticasoneasthmabacteriaCOPDcorticosteroidsinhaled corticosteroidsmicrobiome

Identifiers

PMID36342141
PMCPMC9769713
OpenAlexW4308373098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.